Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;51(2):130-136.
doi: 10.15586/aei.v51i2.779. eCollection 2023.

Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions

Gözde Köycü Buhari  1 , İlkay Koca Kalkan  2 , Hale Ateş  2 , Sakine Nazik Bahçecioğlu  2 , Şenay Demir  2 , Selma Yeşilkaya  2 , Gürgün Tuğçe Vural Solak  2 , Kurtuluş Aksu  2 , Ferda Öner Erkekol  3
Affiliations

Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions

Gözde Köycü Buhari et al. Allergol Immunopathol (Madr). .

Abstract

Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients' demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211-256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs.

Keywords: breakthrough reaction; chemotherapy; desensitization; hypersensitivity reaction; platin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

References

    1. 1. Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother. 2012;61(9):1575–1584. 10.1007/s00262-012-1273-x - DOI
    1. 2. Castells MC. Hypersensitivity to antineoplastic agents. Curr Pharm Des. 2008;14(27):2892–2901. 10.2174/138161208786369803 - DOI
    1. 3. Vervloet D, Durham S. Adverse reactions to drugs. BMJ. 1998;316(7143):1511–1514. 10.1136/bmj.316.7143.1511 - DOI
    1. 4. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53(1):121–122. 10.1006/gyno.1994.1098 - DOI
    1. 5. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol. 2006;6(4):271–277. 10.1097/01.all.0000235900.57182.15 - DOI

MeSH terms

LinkOut - more resources